Fanconi Anemia Drug: Promising Advancements Fanconi Ane Drug Undergoes Successful Clinical Trials

Encouraged by the phase 1/2 results, the drug developer has initiated a phase 2 expansion clinical trial of FT-2102. This new trial will enroll approximately 30 additional FA patients to further evaluate safety and biological activity. Fanconi Anemia Drug will receive twice weekly doses of FT-2102 for 24 weeks. The primary endpoint is the percentage of patients who show increases in neutrophil and/or platelet counts. Additional measures will assess changes in chromosomal breakage in bone marrow and blood cells.

Get More Insights On Fanconi Anemia Drug
https://www.insightprobing...